Predictive value of neutrophil-lymphocyte ratio and its dynamic change in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

Wang WenJun; Zhao Yan; Xia DongDong; Wang EnXin; Liu Lei; Han GuoHong

doi:10.3969/j.issn.1001-5256.2016.06.024

Issue 6

Jun. 2016

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(6): 1139-1144

PDF( 1816 KB)

Predictive value of neutrophil-lymphocyte ratio and its dynamic change in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

DOI: 10.3969/j.issn.1001-5256.2016.06.024

Research funding:

Published Date: 2016-06-20

Abstract

Abstract

Objective To investigate the predictive value of neutrophil- lymphocyte ratio(NLR) and its dynamic change in patients with hepatocellular carcinoma(HCC) undergoing transarterial chemoembolization(TACE).Methods The patients who were diagnosed with HCC and treated with TACE in Xijing Hospital of Digestive Disease of Fourth Military Medical University from January 2010 to December2014 were enrolled.The factors including NLR were recorded at baseline and 3 days and 1 month after TACE.The receiver operating characteristic(ROC) curve was used to determine the cut- off value of NLR.The t- test was used for comparison of continuous data between groups,the chi- square test was used for comparison of categorical data between groups,the Kaplan- Meier method was used to calculate survival rates,and univariate and multivariate Cox regression analyses were used for prognostic analysis.Results A total of 427 patients were enrolled.The median value of baseline NLR was 2.4;at 3 days after surgery,NLR increased and the median value reached 6.2;at 1month after surgery,NLR decreased to the baseline level.The cut- off values at baseline,3 days after surgery,and 1 month after surgery were 2.5,9.7,and 2.5,respectively.At baseline,3 days after surgery,and 1 month after surgery,the median survival time showed significant differences between the low- NLR group and the high- NLR group(χ2= 10.529,8.388,and 6.679,all P < 0.05).The multivariate Cox regression analysis showed that the baseline NLR > 2.5 was the independent predictor for survival difference in HCC patients.In the group with low NLR at baseline and 3 days after surgery,the group with high NLR at baseline or 3 days after surgery,and the group with high NLR at baseline and 3 days after surgery,the median survival time was 28.0,21.0,and 10.1 months,respectively,and showed a significant difference between groups(χ2= 19.846,P < 0.001).In the group with low NLR at baseline and 1 month after surgery,the group with high NLR at baseline or 1 month after surgery,and the group with high NLR at baseline and 1 month after surgery,the median survival time was 29.4,21.0,and 15.4 months,respectively,and showed a significant difference between groups(χ2= 11.424,P = 0.003).Conclusion Baseline NLR and its dynamic change can be used to predict the prognosis in HCC patients receiving TACE.
- carcinoma,
- hepatocellular,
- chemoembolization,
- therapeutic

FullText(HTML)

References(38)

References

[1]CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.

[2]LLOVET JM,REAL MI,MONTANA X,et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial[J].Lancet,2002,359(9319):1734-1739.

[3]LO CM,NGAN H,TSO WK,et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J].Hepatology,2002,35(5):1164-1171.

[4] CAMMA C,SCHEPIS F,ORLANDO A,et al.Transarterial chemoembolization for unresectable hepatocellular carcinoma:meta-analysis of randomized controlled trials[J].Radiology,2002,224(1):47-54.

[5]LLOVET JM,BRUIX J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:chemoembolization improves survival[J].Hepatology,2003,37(2):429-442.

[6] BRUIX J,SHERMAN M,American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma:an update[J].Hepatology,2011,53(3):1020-1022.

[7]European Association for the Study of the Liver,European Organisation for Research and Treatment of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J].JHepatol,2012,56(4):908-943.

[8]LUO Y,SHE DL,XIONG H,et al.Pretreatment neutrophil to lymphocyte ratio as a prognostic predictor of urologic tumors:a systematic review and meta-analysis[J].Medicine(Baltimore),2015,94(40):e1670.

[9] SUN W,ZHANG L,LUO M,et al.Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma:neutrophil-lymphocyte ratio and platelet-lymphocyte ratio[J].Head Neck,2016,38(Suppl 1):e1332-e1340.

[10]TURNER N,WONG HL,TEMPLETON A,et al.Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria[J].Int J Cancer,2016,138(3):671-678.

[11] WU G,YAO Y,BAI C,et al.Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients[J].Thorac Cancer,2015,6(3):275-287.

[12] YODYING H,MATSUDA A,MIYASHITA M,et al.Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-tolymphocyte ratio in oncologic outcomes of esophageal cancer:a systematic review and meta-analysis[J].Ann Surg Oncol,2016,23(2):646-654.

[13]HUANG ZL,LUO J,CHEN MS,et al.Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization[J].J Vasc Interv Radiol,2011,22(5):702-709.

[14]MANO Y,SHIRABE K,YAMASHITA Y,et al.Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma:a retrospective analysis[J].Ann Surg,2013,258(2):301-305.

[15]MOTOMURA T,SHIRABE K,MANO Y,et al.Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment[J].J Hepatol,2013,58(1):58-64.

[16]PINATO DJ,SHARMA R.An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma[J].Transl Res,2012,160(2):146-152.

[17]SULLIVAN KM,GROESCHL RT,TURAGA KK,et al.Neutrophil-to-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma:a Western perspective[J].J Surg Oncol,2014,109(2):95-97.

[18]BRUIX J,REIG M,RIMOLA J,et al.Clinical decision making and research in hepatocellular carcinoma:pivotal role of imaging techniques[J].Hepatology,2011,54(6):2238-2244.

[19] TEMPLETON AJ,MCNAMARA MG,SERUGA B,et al.Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors:a systematic review and meta-analysis[J].J Natl Cancer Inst,2014,106(6):dju124.

[20] LOI S,SIRTAINE N,PIETTE F,et al.Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicinbased chemotherapy:BIG 02-98[J].J Clin Oncol,2013,31(7):860-867.

[21]NEAGOE PE,BRKOVIC A,HAJJAR F,et al.Expression and release of angiopoietin-1 from human neutrophils:intracellular mechanisms[J].Growth Factors,2009,27(6):335-344.

[22]GONG Y,KOH DR.Neutrophils promote inflammatory angiogenesis via release of preformed VEGF in an in vivo corneal model[J].Cell Tissue Res,2010,339(2):437-448.

[23]FU SJ,SHEN SL,LI SQ,et al.Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy[J].Med Oncol,2013,30(4):721.

[24]GOMEZ D,FARID S,MALIK HZ,et al.Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma[J].World J Surg,2008,32(8):1757-1762.

[25]LAI Q,CASTRO SANTA E,RICO JURI JM,et al.Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer[J].Transpl Int,2014,27(1):32-41.

[26]XIAO GQ,LIU C,LIU DL,et al.Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation[J].World J Gastroenterol,2013,19(45):8398-8407.

[27] WANG GY,YANG Y,LI H,et al.A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation[J].PLo S One,2011,6(9):e25295.

[28]BERTUZZO VR,CESCON M,RAVAIOLI M,et al.Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers[J].Transplantation,2011,91(11):1279-1285.

[29] FAN W,ZHANG Y,WANG Y,et al.Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization[J].PLo S One,2015,10(3):e0119312.

[30]MCNALLY ME,MARTINEZ A,KHABIRI H,et al.Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization[J].Ann Surg Oncol,2013,20(3):923-928.

[31] ZHENG YB,ZHAO W,LIU B,et al.The blood neutrophil-tolymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib[J].Asian Pac J Cancer Prev,2013,14(9):5527-5531.

[32]LI X,CHEN ZH,MA XK,et al.Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma[J].Tumour Biol,2014,35(11):11057-11063.

[33] OH BS,JANG JW,KWON JH,et al.Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma[J].BMC Cancer,2013,13(1):78.

[34]HARIMOTO N,SHIRABE K,NAKAGAWARA H,et al.Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation:with special reference to neutrophil/lymphocyte ratio[J].Transplantation,2013,96(11):1008-1012.

[35]HALAZUN KJ,HARDY MA,RANA AA,et al.Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma[J].Ann Surg,2009,250(1):141-151.

[36] XIAO WK,CHEN D,LI SQ,et al.Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma:a meta-analysis[J].BMC Cancer,2014,14(1):117.

[37]KUDO M,IMANAKA K,CHIDA N,et al.Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J].Eur JCancer,2011,47(14):2117-2127.

[38] LENCIONI R,LLOVET JM,HAN G,et al.Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC:the SPACE trial[J].J Hepatol,2016,64(5):1090-1098.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2352) PDF downloads(448)

Predictive value of neutrophil-lymphocyte ratio and its dynamic change in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

DOI: 10.3969/j.issn.1001-5256.2016.06.024

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Predictive value of neutrophil-lymphocyte ratio and its dynamic change in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

DOI: 10.3969/j.issn.1001-5256.2016.06.024

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content